BIELBioElectronics Corp.

About BioElectronics Corp. (BIEL)

BioElectronics Corp. (BIEL) is a Medical Devices company headquartered in Frederick, MD, United States whose shares trade over-the-counter on the Pink tier.

BioElectronics develops & commercializes electrical stimulation/neuromodulation technology. Its flagship technology is wearable, non-thermal pulsed shortwave therapy (PSWT), which is used to treat and manage a variety of chronic neurological disorders such as chronic pain. The company boasts 4 FDA 510 (k) clearances for its devices, backed by safety & effectiveness data from 5 randomized, controlled clinical trials and numerous other registry trials. These clearances allow for two broad indications in the treatment of pain, for all anatomical sites: 1) postoperative pain (prescription); and 2) musculoskeletal pain (OTC). The Company holds market authorization in the European Union (CE mark) & MDSAP countries (USA, Canada & Australia). The Company's strategy is to prioritize its core capabilities of manufacturing, research and development of PSWT technology. The firm's focus is in developing new indications for use/market authorizations & seeking commercial partners with strong marketing & selling expertise. This has resulted in 3 major sources of revenue: 1) US OTC sales for musculoskeletal pain via marketing partners such as KT Health, LLC & DonJoy, LLC who sell custom-branded devices into the consumer retail markets; 2) US sales for postoperative pain through a 1099 sales force, who sell RecoveryRx to medical professionals; 3) International sales via our international distributor partners. http://www.actipatch.com/pharmacy

Products and services

BioElectronics is an electroceutical company that develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. Our innovative pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications. In February 2017, BioElectronics announced that it received over-the-counter use market clearance from the US FDA for ActiPatch® for the adjunctive treatment of musculoskeletal pain related to plantar fasciitis of the heel, and osteoarthritis of the knee. On July 1, 2019, the Company announced that it has received market clearance from the United States Food and Drug Administration (US FDA) for its RecoveryRx® medical device, for the treatment of postoperative pain. In February 2020, BioElectronics obtained a new 510(k) clearance from the U.S. FDA, granting over-the-counter marketing clearance for the drug-free ActiPatch® medical device, to cover all musculoskeletal pain complaints. This paves the way for new products to treat all medical claims for musculoskeletal pain, including in the back, knee, hips, wrists, elbow, and ankle.

BIEL key facts

Ticker symbol

BIEL

Market tier

Pink

Sector

Healthcare

Industry

Medical Devices

Headquarters

Frederick, MD, United States

Country of incorporation

US

Year of incorporation

2000

Employees

8

Estimated market cap

$4.94M (as of Apr 10, 2025)

Shares outstanding

24,705,066,971

Reporting standard

Alternative Reporting Standard

Audit status

Unaudited

Fiscal year end

12/31

Latest filing

Annual Report (Dec 31, 2023)

BioElectronics Corp. leadership

• Kelly A Whelan — CEO

Explore more: Medical Devices stocks · Healthcare sector · Pink stocks · OTC stocks starting with B